News | February 08, 2024
MIRA Pharmaceuticals announces collaboration with Pharmaseed
Studies will Investigate Antidepressant Properties of Ketamir to Position for Initial IND Application in 2024
Studies will Investigate Antidepressant Properties of Ketamir to Position for Initial IND Application in 2024
Mindset disagrees with and denies the allegations set forth from Reunion.
Expands AbbVie's neuroscience portfolio, adding first-in-class modulators of the synaptic vesicle protein 2A, including lead molecule SDI-118 currently in Phase 1b studies
Deplesin is an add-on therapy to gold standard agents like lithium, valproic acid, and carbamazepine, supporting patients in ways that prescription medications often cannot
Subscribe To Our Newsletter & Stay Updated
